While the interaction with the major histocompatibility complex (MHC II) may induce macrophages and CD8+ activation against tumor cells, it may also lead to differentiation into regulatory T cells (such as FOXP3+ cells) and inhibit the immune response [56]. This evidence concerns the gene FOXP3 and neoplasm.